我武生物皮炎诊断贴剂 02 贴获批临床，为过敏性疾病诊疗注入新活力

Core Insights - Zhejiang Iwu Biological Technology Co., Ltd. has made significant progress in the field of allergic disease diagnostics with the approval of its "Dermatitis Diagnostic Patch 02" for clinical trials by the National Medical Products Administration [1][5] Group 1: Product Development - The "Dermatitis Diagnostic Patch 02" focuses on diagnosing three common allergens: Kathon, p-phenylenediamine, and formaldehyde, which are frequently encountered in daily life and are known to cause allergic contact dermatitis [4][6] - The clinical trial process will follow a rigorous drug development protocol, including Phase I, II, and III trials to assess safety, efficacy, and dosage [5][6] Group 2: Market Position and Impact - Iwu Biological is a leading domestic pharmaceutical company specializing in the research and innovation of allergic disease diagnostics and treatments, with a strong R&D team and a history of successful product launches [6][7] - The approval of the "Dermatitis Diagnostic Patch 02" is expected to enhance the company's competitiveness in the diagnostic market and contribute to the development of the allergic disease diagnostics sector in China [6][7]